EG25755A - Oxazol deriatives - Google Patents

Oxazol deriatives

Info

Publication number
EG25755A
EG25755A EG2002050495A EG2002050495A EG25755A EG 25755 A EG25755 A EG 25755A EG 2002050495 A EG2002050495 A EG 2002050495A EG 2002050495 A EG2002050495 A EG 2002050495A EG 25755 A EG25755 A EG 25755A
Authority
EG
Egypt
Prior art keywords
deriatives
oxazol
oxazol deriatives
Prior art date
Application number
EG2002050495A
Other languages
English (en)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of EG25755A publication Critical patent/EG25755A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EG2002050495A 2001-05-15 2002-05-14 Oxazol deriatives EG25755A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15

Publications (1)

Publication Number Publication Date
EG25755A true EG25755A (en) 2012-06-26

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
EG2002050495A EG25755A (en) 2001-05-15 2002-05-14 Oxazol deriatives

Country Status (39)

Country Link
US (1) US6642389B2 (fr)
EP (1) EP1392295B1 (fr)
JP (2) JP4330883B2 (fr)
KR (1) KR100654516B1 (fr)
CN (1) CN100356917C (fr)
AR (1) AR035892A1 (fr)
AT (1) ATE327753T1 (fr)
AU (1) AU2002342244B2 (fr)
BG (1) BG66316B1 (fr)
BR (1) BRPI0209821B1 (fr)
CA (1) CA2445145C (fr)
CY (1) CY1105160T1 (fr)
CZ (1) CZ20033037A3 (fr)
DE (1) DE60211891T2 (fr)
DK (1) DK1392295T3 (fr)
EC (1) ECSP034848A (fr)
EG (1) EG25755A (fr)
ES (1) ES2264482T3 (fr)
GT (1) GT200200085A (fr)
HK (1) HK1067534A1 (fr)
HR (1) HRP20030889B1 (fr)
HU (1) HU230224B1 (fr)
IL (2) IL158589A0 (fr)
JO (1) JO2282B1 (fr)
MA (1) MA27025A1 (fr)
ME (1) ME01310B (fr)
MX (1) MXPA03010435A (fr)
MY (1) MY136761A (fr)
NO (1) NO333833B1 (fr)
NZ (1) NZ529033A (fr)
PA (1) PA8544901A1 (fr)
PE (1) PE20021152A1 (fr)
PL (1) PL208074B1 (fr)
PT (1) PT1392295E (fr)
RU (1) RU2278859C2 (fr)
SI (1) SI1392295T1 (fr)
SK (1) SK287842B6 (fr)
WO (1) WO2002092084A1 (fr)
ZA (1) ZA200308538B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72625C2 (uk) * 2000-05-26 2005-03-15 Ніппон Сіняку Ко., Лтд. Гетероциклічні сполуки
KR100654516B1 (ko) * 2001-05-15 2006-12-05 에프. 호프만-라 로슈 아게 당뇨병 치료에서 ｐｐａｒ-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
CA2462200A1 (fr) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetiques de metallopeptides biologiquement actifs
AU2003214932A1 (en) 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
JP4533141B2 (ja) * 2002-08-30 2010-09-01 エフ．ホフマン−ラ ロシュ アーゲー ＰＰＡＲα及びＰＰＡＲγアゴニストとしての新規２−アリールチアゾール化合物
AR041481A1 (es) 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CN1738807A (zh) * 2002-11-15 2006-02-22 卡地拉健康护理有限公司 取代的芳烷基衍生物
CN100343250C (zh) * 2002-11-25 2007-10-17 霍夫曼-拉罗奇有限公司 吲哚衍生物
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) * 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
CA2543247A1 (fr) * 2003-11-05 2005-06-02 F. Hoffmann-La Roche Ag Composes a cycle benzenique constituant des activateurs de ppar
CN1875002B (zh) 2003-11-05 2011-08-03 霍夫曼-拉罗奇有限公司 作为ppar激动剂的苯基衍生物
WO2005056536A1 (fr) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Agents antidiabetiques a activite anti-ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2564563C (fr) 2004-05-03 2011-07-05 F. Hoffmann-La Roche Ag Derives d'indolyle en tant que modulateurs du recepteur x du foie
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
WO2006108491A1 (fr) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Procede ameliore de preparation de nitriles d'oxazole
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
AU2008221718A1 (en) * 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
DK2100604T3 (da) * 2008-03-10 2012-07-23 Nestec Sa Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser
CA2723727A1 (fr) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Derives d'oxazolobenzimidazole
EP2382569A2 (fr) 2008-12-23 2011-11-02 Roche Diagnostics GmbH Procédé de gestion et système pour la mise en uvre, l'exécution, le recueil de données et l'analyse de données d'une procédure de recueil structurée qui fonctionne sur un dispositif de recueil
WO2010084066A1 (fr) * 2009-01-23 2010-07-29 F. Hoffmann-La Roche Ag Composition pharmaceutique comprenant de l'aleglitazar
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
SI2585452T1 (sl) 2009-12-07 2015-12-31 F. Hoffmann-La Roche Ag Postopek za pripravo derivatov propionske kisline
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (fr) 2012-05-31 2013-12-05 Ratiopharm Gmbh Formes à l'état solide d'aleglitazar sodique
JP2015528476A (ja) * 2012-09-12 2015-09-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ （Ｓ）−２−メトキシ−３−｛４−［２−（５−メチル−２−フェニル−オキサゾール−４−イル）−エトキシ］−ベンゾ［ｂ］チオフェン−７−イル｝−プロピオン酸の及びその塩の固体形態
EP3402482A1 (fr) 2015-11-18 2018-11-21 H. Hoffnabb-La Roche Ag Aleglitazar pour traiter la néphropathie diabétique
US20190350955A1 (en) 2016-06-30 2019-11-21 Inserm (Institut National De La Sante Et De La Recherche Medicale Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (fr) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar destiné à être utilisé dans le traitement ou la prévention d'accidents cardiaques majeurs
WO2020201263A1 (fr) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement et la prévention du remodelage cardiaque
CA3227149A1 (fr) * 2021-08-13 2023-02-16 Alebund Pharmaceuticals (Hong Kong) Limited Composes deuteres
WO2024100051A1 (fr) 2022-11-08 2024-05-16 Genfit Agoniste ppar-alpha/gamma destiné à être utilisé dans le traitement de l'insuffisance hépatique

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US6048883A (en) 1992-07-03 2000-04-11 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
ZA9711051B (en) 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
EP1073643B1 (fr) 1998-04-23 2004-12-29 Dr. Reddy's Laboratories Ltd. Nouveaux composes heterocycliques, leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
ATE319702T1 (de) 1999-08-02 2006-03-15 Verfahren zur herstellung von benzothiophen- derivaten
ES2286137T3 (es) * 2000-08-23 2007-12-01 Eli Lilly And Company Derivados de acido oxazolil-arilpropionico y su uso como agonistas de ppar.
KR100654516B1 (ko) * 2001-05-15 2006-12-05 에프. 호프만-라 로슈 아게 당뇨병 치료에서 ｐｐａｒ-알파 및 -감마 활성제로서사용하기 위한 카복실산 치환된 옥사졸 유도체

Also Published As

Publication number Publication date
ES2264482T3 (es) 2007-01-01
HUP0400992A3 (en) 2007-11-28
KR100654516B1 (ko) 2006-12-05
SK287842B6 (sk) 2011-12-05
BG66316B1 (bg) 2013-04-30
CA2445145C (fr) 2008-10-14
SI1392295T1 (sl) 2006-10-31
JP4330883B2 (ja) 2009-09-16
HU230224B1 (hu) 2015-10-28
ZA200308538B (en) 2005-04-26
MA27025A1 (fr) 2004-12-20
HRP20030889A2 (en) 2005-08-31
MY136761A (en) 2008-11-28
MXPA03010435A (es) 2004-03-09
HUP0400992A2 (hu) 2004-08-30
IL158589A (en) 2010-11-30
PL208074B1 (pl) 2011-03-31
HRP20030889B1 (en) 2011-10-31
PE20021152A1 (es) 2003-02-07
BRPI0209821B1 (pt) 2016-09-27
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
DK1392295T3 (da) 2006-10-02
EP1392295A1 (fr) 2004-03-03
NO20035086L (no) 2003-11-14
ECSP034848A (es) 2003-12-24
AR035892A1 (es) 2004-07-21
US6642389B2 (en) 2003-11-04
EP1392295B1 (fr) 2006-05-31
JP2004529174A (ja) 2004-09-24
AU2002342244B2 (en) 2005-06-16
US20030055265A1 (en) 2003-03-20
GT200200085A (es) 2003-01-16
DE60211891D1 (de) 2006-07-06
NO333833B1 (no) 2013-09-30
BR0209821A (pt) 2004-06-01
ME01310B (fr) 2011-10-10
CA2445145A1 (fr) 2002-11-21
CZ20033037A3 (cs) 2004-06-16
RU2003134150A (ru) 2005-06-10
CN100356917C (zh) 2007-12-26
SK13852003A3 (en) 2004-10-05
CN1509173A (zh) 2004-06-30
PT1392295E (pt) 2006-09-29
BG108362A (bg) 2005-03-31
NZ529033A (en) 2005-06-24
NO20035086D0 (no) 2003-11-14
HK1067534A1 (en) 2005-04-15
WO2002092084A1 (fr) 2002-11-21
KR20030096397A (ko) 2003-12-24
JO2282B1 (en) 2005-09-12
JP2009138011A (ja) 2009-06-25
CY1105160T1 (el) 2009-11-04
PA8544901A1 (es) 2003-01-24
DE60211891T2 (de) 2007-05-24
ATE327753T1 (de) 2006-06-15
IL158589A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
EG25755A (en) Oxazol deriatives
DE60209787D1 (en) Flächiges implantat
DE50201180D1 (en) Organopolysiloxan/polyharnstoff/polyurethan-blockcopolymere
DE60213216D1 (en) Metalloproteinaseinhibitoren
DE50209614D1 (en) 2-heteroarylcarbonsäureamide
DE50211022D1 (en) Heteroarylcarbonsäureamide
DE60210819D1 (en) Pyrazolopyridazinderivate
DE60141364D1 (en) Polyphenylensulfidharzzusammensetzung
DE60141362D1 (en) Ösophagus-stoma-knopf
DE50202633D1 (en) Ophthalmoskop
AU2002360430A8 (en) 14-methyl-epothilones
DE60107296D1 (en) Kabelverstärkerverbindungsanordnung
DE60204140D1 (en) 5-ethyl-imidazotriazinone
HU0400176V0 (en) Improved gasketseal
DE50206483D1 (en) Displaymodul
DE50201028D1 (en) Diarylgelbpigmentpraeparationen
DE50214962D1 (en) Heterocyclylarylsulfonamide
DE60206072D1 (en) Aroylpyridinone
AU2002313943A8 (en) Electromobile
AU2001100134A4 (en) Enviro-trap
GB0112053D0 (en) Bacsac
CA92978S (en) Photo-changer
CA93126S (en) Titlt-latch
CA92665S (en) Bedboard
CA91502S (en) Bedboard